Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer

Purpose: The aim of the study was to examine whether TMPRSS2:ERG fusion or SPINK1 protein expression is associated with hormone responsiveness of prostate cancer and can thus be used as a biomarker. Experimental Design: Diagnostic needle biopsies from prostate cancer patients primarily treated by endocrine therapy were evaluated for TMPRSS2:ERG fusion with fluorescence in situ hybridization and SPINK1 protein expression with immunohistochemistry. Results: The frequency of TMPRSS2:ERG fusion in 178 biopsies of hormonally treated patients was 34%. Of the fusion-positive cases, 71% showed deletion between the two genes, and 23% showed gain of the fusion. The fusion was associated with high Ki-67 staining (P = 0.001), age at diagnosis (P = 0.024), and tumor area (P = 0.006), but not with Gleason score, T stage, M stage, prostate-specific antigen (PSA), or progression-free survival. Strong positive SPINK1 expression was found in 11% (21 of 186) of the biopsies. SPINK1-positive cases had significantly shorter progression-free survival compared with SPINK1-negative cases (P = 0.001). The expression was not associated with any other clinicopathologic variables studied. In a multivariate analysis, SPINK1 expression showed independent prognostic value, with a relative risk of 2.3 (95% confidence interval, 1.1-4.6). SPINK1 expression and the fusion were not associated with each other. Conclusions: There was no association between TMPRSS2:ERG fusion and prognosis, suggesting that TMPRSS2:ERG rearrangement does not implicate hormone dependence of the cancer. SPINK1 expression, found in ∼10% of prostate cancers, was associated with aggressive form of the disease and could serve as a biomarker in endocrine-treated prostate cancer. Clin Cancer Res; 16(10); 2845–51. ©2010 AACR.

[1]  M. Rubin,et al.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.

[2]  L. Collette,et al.  Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer. , 2010, European urology.

[3]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[4]  M. Ohmuraya,et al.  Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor , 2009, Molecular Cancer Research.

[5]  S. Dhanasekaran,et al.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.

[6]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[7]  U. Stenman,et al.  Biochemistry and Clinical Role of Trypsinogens and Pancreatic Secretory Trypsin Inhibitor , 2006, Critical reviews in clinical laboratory sciences.

[8]  R. Shah,et al.  CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .

[9]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[10]  R. Shah,et al.  Characterization of TMPRSS 2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer , 2008 .

[11]  T. Visakorpi,et al.  Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[12]  U. Stenman,et al.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.

[13]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[14]  T. Mori,et al.  Response to IL-6 stimulation of human hepatoblastoma cells: production of pancreatic secretory trypsin inhibitor. , 1990, Biological chemistry Hoppe-Seyler.

[15]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[16]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[17]  O. Itkonen,et al.  Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. , 1993, Journal of immunological methods.

[18]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[19]  Yao-Tseng Chen,et al.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.

[20]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[21]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[23]  E. Petricoin,et al.  Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. , 2009, The Journal of urology.

[24]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[25]  M. Gleave,et al.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.

[26]  J. Brooks,et al.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.

[27]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.